MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

SARS-CoV-2 variants

Search medical newsFind research, conditions and clinical updates
  • Home
  • SARS-CoV-2 variants
思春期者におけるPHH-1V COVID-19ワクチンの異種ブースターとしての免疫原性と安全性
Posted inClinical Updates Infectious Diseases Pediatrics

Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents

Posted by By MedXY 10/31/2026
PHH-1V, a protein-based COVID-19 vaccine, is shown to be a safe and effective heterologous booster in adolescents, generating strong and lasting immune responses against multiple virus variants.
Read More
Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults: A Comprehensive Review of Recent Evidence
Posted inClinical Updates news Public Health

Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults: A Comprehensive Review of Recent Evidence

Posted by By MedXY 08/07/2026
This review synthesizes recent evidence on the effectiveness of 2024-2025 COVID-19 vaccines in adults, highlighting moderate protection against symptomatic illness, hospitalization, and critical outcomes, with emphasis on waning immunity and variant-specific dynamics.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Comparative Clinical Performance and Color Matching of One-Shade vs. Multi-Shade Flowable Composites in Non-Carious Cervical Lesions: An 18-Month Double-Blind Randomized Trial
  • Izalontamab Brengitecan in Heavily Pretreated HR+/HER2- Breast Cancer: Insights from the PANKU-Breast01 Phase 3 Trial in China
  • Long-Term Clinical Outcomes of Zika-Related Microcephaly: Insights from the First Five Years of Life
  • Comparative Real-World Effectiveness and Retention of Biologic DMARDs in Psoriatic Arthritis: Insights from an Emulated Multicentre Trial
  • Rising Trends and Outcomes of MASLD in Liver Transplantation: Implications for Early Detection and Management
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top